Genes associated with Erdheim-Chester disease also linked to cancer

March 31, 2017 by Jeannine Mjoseth, NIH/National Human Genome Research Institute
Monocyte/macrophage cell function is impaired in Erdheim- Chester Disease leading to their accumulation causing systemic inflammation and organ damage. Credit: Shutterstock/somersault1824.

National Human Genome Research Institute (NHGRI) researchers have identified new genes associated with the Erdheim-Chester disease (ECD) and some possible new therapies. Findings on this ultra-rare disease, found in approximately 600 people in the world, were published in Blood Advances.

"The discovery of new genes associated with ECD provides hope for improving the diagnoses of a disease that affects so many parts of the body. We also hope it will help us identify new treatments," said Juvianee I. Estrada-Veras, M.D., clinical investigator and staff clinician in NHGRI's Medical Biochemical Genetics Residency Program. "Our work on ECD builds on the institute's goals to advance medical knowledge about rare diseases and to potentially provide insights into more common disorders."

ECD is caused by the accumulation of specialized called histiocytes in different organs. The resulting inflammation damages organs and tissues throughout the body, causing them to become thickened, dense and scarred. Histiocytes normally function to destroy foreign substances and protect the body from infection. ECD has no standard therapy, although consensus guidelines for clinical management were published in 2014.

Between 2011 and 2015, researchers examined 60 adults with ECD at the NIH Clinical Center. Of 59 samples that were available for molecular testing, half had BRAF V600E gene mutations, which is sometimes seen in colon cancer, lung cancer, thyroid cancer, brain tumors and some blood cancers. Other patients had mutations in genes of the MAPK pathway, which controls cell growth and proliferation. These findings indicate that, despite the presence of inflammation and the absence of metastases (spread of from the place where they first formed to another part of the body), ECD should be considered a type of cancer and treated by oncologists, researchers wrote.

Until now, the most common treatment for ECD has been interferon, a drug that interferes with the division of cells and slows tumor growth. Some patients with severe forms of disease can succumb to the illness even with treatment. The mortality rate for ECD has been estimated at 60 percent at 3 years from the time of diagnosis.

Researchers suggested that therapies that stop the growth and proliferation of by blocking the MAPK pathway—vemurafenib, dabrafenib and trametinib—may provide new hope for treating and improving the survival of people with ECD. A therapeutic trial of dabrafenib and trametinib is now enrolling new ECD patients with BRAF V600E mutations #NCT02281760 .

Explore further: Doctors treat deadly cancerous disorders with gene-guided, targeted therapy

More information: Juvianee I. Estrada-Veras et al. The clinical spectrum of Erdheim-Chester disease: an observational cohort study, Blood Advances (2017). DOI: 10.1182/bloodadvances.2016001784

Related Stories

Doctors treat deadly cancerous disorders with gene-guided, targeted therapy

February 16, 2017
Genomic testing of biopsies from patients with deadly, treatment-resistant cancerous blood syndromes called histiocytoses allowed doctors to identify genes fueling the ailments and use targeted molecular drugs to successfully ...

New colorectal cancer targeted therapy combination shows promise

January 18, 2017
New SWOG study results show significantly better outcomes for patients with a treatment-resistant form of metastatic colorectal cancer when the BRAF inhibitor vemurafenib is added to a standard treatment. The findings, for ...

Study identifies novel treatment resistance mechanism in BRAF-mutant melanoma

August 8, 2016
A Massachusetts General Hospital (MGH) research team has identified an additional mechanism for resistance to targeted treatment for BRAF-mutant melanoma. Their paper, receiving advance online publication in Nature Medicine, ...

New molecular targets identified in some hard-to-treat melanomas

December 17, 2013
Two novel BRAF fusions were identified in melanomas previously considered to be negative for molecular targets, and melanomas with these fusions were found to be potentially sensitive to anticancer drugs called MEK inhibitors, ...

Studies identify cell-signaling pathway alterations responsible for melanoma drug resistance

November 22, 2013
Genomic profiling of treatment-resistant, BRAF-mutated melanomas revealed multiple gene alterations, mostly involving a cell-signaling pathway called the MAPK pathway, and more potent forms of existing drugs and drugs targeting ...

Preclinical study indicates potential for novel inhibitor to overcome drug resistance induced by RAF, MEK inhibitors

April 8, 2013
A new class of investigational medicines may help to treat patients with cancers driven by mutations in genes such as BRAF or KRAS/NRAS, including those patients who have become resistant to therapies that target BRAF directly, ...

Recommended for you

Researchers discover cell structure that plays a role in epigenetic inheritance

May 22, 2018
We know a lot about how genes get passed from parent to child, but scientists are still unraveling how so-called epigenetic information—instructions about which genes to turn on and off—is conveyed from generation to ...

Fruit flies: 'Living test tubes' to rapidly screen potential disease-causing human gene

May 22, 2018
It all began with one young patient; a 7-year old boy who was born without a thymus, an important organ of the immune system, and without functional immune cells. The boy also presented with cardiac and skeletal defects, ...

Advance genetics study identifies virulent strain of tuberculosis

May 22, 2018
LSTM's Dr. Maxine Caws is co-lead investigator on an advanced genetics study published in Nature Genetics, which has shown that a virulent strain of tuberculosis (TB) has adapted to transmit among young adults in Ho Chi Minh ...

Cell types underlying schizophrenia identified

May 22, 2018
Scientists at Karolinska Institutet in Sweden and University of North Carolina have identified the cell types underlying schizophrenia in a new study published in Nature Genetics. The findings offer a roadmap for the development ...

New brain development disorder identified by scientists

May 22, 2018
Researchers have identified a new inherited neurodevelopmental disease that causes slow growth, seizures and learning difficulties in humans.

New data changes the way scientists explain how cancer tumors develop

May 21, 2018
A collaborative research team has uncovered new information that more accurately explains how cancerous tumors grow within the body. This study is currently available in Nature Genetics.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.